Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

South Korea's acting President Choi Sang-mok on Wednesday said he hoped for a swift agreement within the country's parliament ...

CSL shares continued to slide after Tuesday's selloff, even as Morningstar hiked its valuation in the biopharmaceutical giant.

The Seoul government will hold an export strategy meeting next week to discuss measures aimed at minimizing the impact of the ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...

Traders were on guard after Federal Reserve Chair Jerome Powell said on Tuesday that the central bank is in no hurry to lower ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

Goldman Sachs analyst Paul Choi downgraded the stock from "Neutral" to "Sell," setting a price target of $12, which is ...